Summary Prostaglandins are synthesized from arachidonic acid by the enzyme cyclo-oxygenase. There are two isoforms of cyclooxygenases: COX-1 (a constitutive form) and COX-2 (an inducible form). COX-2 has recently been categorized as an immediate-early gene and is associated with cellular growth and differentiation. The purpose of this study was to investigate the effects of exogenous dimethylprostaglandin E2 (dmPGE2) on prostate cancer cell growth. Results of these experiments demonstrate that administration of dmPGE2 to growing PC-3 cells significantly increased cellular proliferation (as measured by the cell number), total DNA content and endogenous PGE2 concentration. DmPGE2 also increased the steady-state mRNA levels of its own inducible synthesizing enzyme, COX-2, as well as cellular growth to levels similar to those seen with fetal calf serum and phorbol ester. The same results were observed in other human cancer cell types, such as the androgen-dependent LNCaP cells, breast cancer MDA-MB-134 cells and human colorectal carcinoma DiFi cells. In PC-3 cells, the dmPGE2 regulation of the COX-2 mRNA levels was both time dependent, with maximum stimulation seen 2 h after addition, and dose dependent on dmPGE2 concentration, with maximum stimulation seen at 5 [sg ml-'. The non-steroidal anti-inflammatory drug flurbiprofen (5 FM), in the presence of exogenous dmPGE2, inhibited the up-regulation of COX-2 mRNA and PC-3 cell growth. Taken together, these data suggest that PGE2 has a specific role in the maintenance of human cancer cell growth and that the activation of COX-2 expression depends primarily upon newly synthesized PGE2, perhaps resulting from changes in local cellular PGE2 concentrations.
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Keywords: prostaglandin E2; cyclo-oxygenase-2; prostate cancer; non-steroidal anti-inflammatory drug; flurbiprofen Arachidonic acid (AA) is derived from linoleic acid (LA) through two major reactions: desaturation (catalysed by delta-6 desaturase) and elongation (by elongase) of LA to produce dihomogammalinolenic acid (20:3) intermediate, followed by a desaturation step catalysed by delta-5-desaturase to produce AA (Zurier, 1993) . AA is then transformed to prostaglandins (PGs) and thromboxanes (TXs) by the enzyme prostaglandin endoperoxide synthase (PES), also referred to as cyclo-oxygenase (COX; EC 1.14.99.1) (Needleman et al, 1986; Smith, 1992) . This enzyme catalyses two enzymatic reactions: oxygenation of AA into PGG2 followed by peroxidation of PGG2 into PGH2 (Needleman et al, 1986) . PGH2 is subsequently isomerized and reduced to the major biologically active prostanoids: PGE2, PGF2a, prostacyclin (PGI2) or thromboxane A2 (Smith, 1992) .
Mammalian cells contain at least two isozymes of cyclooxygenase: COX-1 and COX-2. COX-1 is a well-characterized, constitutively expressed enzyme originally purified from ovine and bovine vesicular glands and platelets (Smith, 1992; Smith et al, 1991) . The cDNA clones of the 2.8-kb COX-l mRNA isolated from ovine (DeWitt and Smith, 1988) , murine (DeWitt et al, 1990) and human tissues (Funk et al, 1991) encodes a protein of approximately 600 amino acids in length. The cDNA clones of the 4.4-kb COX-2 message have been isolated from various tissues of human and animal origin and also encode a protein of about 600 amino acids (Fletcher et al, 1992; Hla and Neilson, 1992) . COX-1 and COX-2 polypeptides share 61% primary sequence identity (Appleby et al, 1994) . The expression of COX-2 mRNA and/or protein, however, has been shown to be induced in a variety of cells following addition of serum in src-transformed chicken fibroblasts (Xie et al, 1991) , differentiation factors such as lipopolysaccharides in human and animal macrophages (Hla and Neilson, 1992) , tumour-promoter phorbol ester , growth factors (Hamasaki et al, 1993 ) and cytokines such as tumour necrosis factor and interleukin la (Chen et al, 1994; Ristimaki et al, 1994) .
There is evidence showing correlation between the levels of arachidonic acid metabolites and tumorigenesis. For example, in the skin model of mouse carcinogenesis, the administration of tumourpromoting agents tetradecanoylphorbacetate (TPA) or 7-bromomethylbenz [a] anthracene to mouse epidermis induces accumulation of high levels of PGE2 (Furstenberger and Marks, 1980; Yamamoto et al, 1992) . Many non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, indomethacin and sulindac, have been shown to inhibit the growth of colon tumours induced by chemical carcinogens in rodents (Narisawa et al, 1982; Reddy et al, 1987) . In addition, recent epidemiological studies with large numbers of human patients show that the frequent use of aspirin or other NSALDs acts as a protective agent against colon and rectal cancers (Thun et al, 1991 (Thun et al, , 1993 . However, it is unclear whether this is due to a direct effect of NSAIDs, mediated by the inhibition of prostaglandin synthesis, or by other factors indirectly associated with NSAID use.
Prostate cancer is one of the commonest cancers in the elderly male population and its aetiology remains unknown. Epidemiological studies on carcinoma of the prostate have revealed a link between the development of disease and consumption of dietary fats (Graham et al, 1983) . Recent studies by Rose and Connolly (Rose and Connolly, 1991; Connolly and Rose, 1992) have shown that growth of the androgen-unresponsive PC-3 human prostate cancer cells is stimulated in vitro by the addition of the omega-6 polyunsaturated LA and inhibited by NSAIDs such as indomethacin, esculetin and piroxicam. The growth effects of essential fatty acids appear to involve both PGs and leukotrienes (LTs), which interconnect with autocrine regulation through epidermal growth factor-related polypeptides Rose and Connolly, 1992) . Moreover, Wahle and coworkers have also shown that human malignant prostatic tissues have significantly reduced AA concentration compared with benign tissue (Chaudry et al, 1991) . When these investigators followed the metabolism of labelled AA, significant amounts of the radioactive label was found in PGE2 in both benign and malignant prostatic tissues, with the malignant tissues converting radiolabelled AA to PGE2 at an almost 10-fold higher rate than benign tissues (Chaudry et al, 1994) . The data suggest a specific role for PGE2 in maintaining the growth of malignant prostatic tissues.
The present studies were designed to investigate the effects of exogenous PGE2 on cellular growth as well as on COX-2 expression in the human prostatic adenocarcinoma PC-3 cell line. We have shown previously that PGE2 acts as an autocrine growth factor in the growth of osteoblast MC3T3-E1 cells (HughesFulford et al, 1992) . PGE2 also up-regulates the expression of immediate-early genes, such as c-fos and c-jun, and increases DNA synthesis and bone cell number in comparison with nontreated cells (Hughes-Fulford et al, 1992) . We reasoned that, if PC-3 is responsive to growth stimulation by linoleic acid, then it may also be responsive to growth stimulation by PGE2. Indeed, our data suggest that PGE2 at the micromolar level is able to stimulate PC-3 cell growth, partly through up-regulation of COX-2 mRNA levels and newly synthesized PGE2. (-1.7-3.4 FtM) (Hughes-Fulford et al, 1992) .
MATERIALS AND METHODS Materials

RNA isolation
RNA was extracted and purified by the acid guanidium thiocyanate-phenol-chloroform extraction method (RNA Stat-60 reagent), according to the procedure recommended by the manufacturer (TelTest 'B', Friendswood, TX, USA). One millilitre of the RNA Stat-60 reagent was added directly to the culture dishes and the cells were scraped and collected into 1.5-ml siliconized microfuge tubes. Two hundred microlitres of chloroform was then added and the tubes were shaken vigorously to extract the RNA and allowed to sit at room temperature for 2-3 min. The homogenate was centrifuged at 12 000 g for 15 min at 4°C. Following centrifugation, the colourless aqueous upper layer was carefully removed and transferred to a fresh tube. An equal volume (550-600 [tl) of isopropanol was then added to the tubes and the samples were stored at 40C overnight. The tubes were centrifuged the next day and the RNA precipitates appeared as a white pellet in the bottom of the tubes. The pellet was washed once with isopropanol and subsequently dried at room temperature for 5-10 min. The RNA was then resuspended in diethylpyrocarbonate-treated (DEPC) water and run on a 0.5% agarose gel. Quantitation of RNA was performed on GeneQuant spectrophotometer (Pharmacia LKB Biotechnology, Piscataway, NJ, USA). Figure 1 Changes in PC-3 cell number (A) and endogenous PGE2 (B) in response to dmPGE2 stimulation. PC-3 cells were plated in six-well plates (1.2 x 105 cells per well) in 4 ml of RPMI-1640 medium containing 2% fetal bovine serum supplemented with antibiotics/antimycotics. The cells were grown for a period of 2 days in the absence and presence of exogenous dmPGE2 (5 1tg ml-1). Each day, the cells were counted for increase in the cell number and the cellular medium was collected for PGE2 concentration measurements, as described in the Materials and methods section. The data are presented as an average ± s.d. of triplicate treatments. **P < 0.05, and ***P < 0.01 (Boehringer Mannheim), Taq DNA polymerase (Gibco BRL), PCR buffer supplied with the Taq DNA polymerase, sense and antisense gene primers and sufficient deionized water to make up the 50 RI total volume. The primers used for priming the COX-2 gene were as follows: sense, 5'-GTG CCT GGT CTG ATG ATG TAT GC; and anti-sense, 5'-CCA TAA GTC CTT TCA AGG AGA ATG. The British Journal of Cancer (1997) 75(8) 10 I ** v *** PCR bands were identified by size after electrophoresis on a 1% agarose gel in tris-acetate-EDTA (TAE) buffer. The gel was run on a Hoeffer mini-gel apparatus at a constant voltage of 125 V for approximately 30 min, stained with ethidium bromide, viewed by UV light, and photographed with a direct-screen instant camera DS-34 (Polaroid, Cambridge, MA, USA). For quantification, the bands of interest were scanned at 400 dpi with an HP Scanjet Ilcx scanner (Hewlett-Packard, Palo Alto, CA, USA) and stored as Macintosh TIFF files. The peak areas and densities were determined using NIH Image 1.55 program written by Wayne Rasband at the US National Institutes of Health, Bethesda, MD, USA. All measurements of increases in COX-2 mRNA have been corrected to the internal standard (P-actin) and are reported as fold of increase from the control in each figure legend.
RT-PCR analysis
Cell number and measurement of DNA content Cell counting was performed using the ZBI Coulter counter (Coulter Electronics, Hialeah, FL, USA) with isotonic buffered saline solution (Baxter, Deerfield, IL, USA) as blanks. Briefly, cells were plated out in Falcon six-well plates (Becton Dickenson, Lincoln Park, NJ, USA) in 0.3% FBS-containing RPMI-1640 medium with and without treatments. Following 24-h and 48-h treatments, cells were trypsinized and collected into 15-ml conical tubes. The trypsin was neutralized by adding 1 ml of mediumcontaining 10% FBS to the sample and 100-i.l volumes were counted using the Coulter counter. Direct measurement of DNA content was performed using the Fluoroskan II fluorometer (Labsystems, Needham Heights, MA, USA). Briefly, cells were plated out in 96-well plates in a total medium volume of 200 p.1. Following 24-h treatment, 3 it1 of Hoechst dye no. 33258 1 mg ml-' (Calbiochem, San Diego, CA, USA) was added to individual wells and incubated for 30 min in the 370C incubator. Cells were then washed three times with phosphate-buffered saline, and the fluorescence was read using the fluorometer with the excitation wavelength set at 346 nm and the emission at 460 nm.
PGE2 analysis
The exogenous PGE2 levels were quantitated using the PGE2 Monoclonal Enzyme Immunoassay Kit (Cayman Chemical, Ann Arbor, MI, USA), according to the protocol recommended by the manufacturer. This kit assay system is very specific for native PGE2 and does not detect dmPGE2 or any prostaglandin of other series (A, B, D or F). The samples contained in the 96-well plate were read at 410 nm using the Dynatech MR5000 Microplate Reader (Dynatech Laboratories, Chantilly, VA, USA), and the data were analysed with the BioLinx 2.0 Software (Dynatech Laboratories) run on an IBM-compatible PC.
RESULTS
Changes in PC-3 cell number and endogenous PGE2 in response to exogenous dmPGE2 administration The effect of exogenous dmPGE2 on the growth of prostatic carcinoma PC-3 cells is shown in Figure lA . PC-3 cells grew linearly from day 0 to day 2. The cell growth rate was highest between days l and 2. Exogenous dmPGE2 at a concentration of 5 gig ml-' was able to increase the cell number by 1.5-fold compared with the control cultures seen at the end of the 2-day treatment period. This increase in cell proliferation was primarily due to a 2.5-fold increase in growth rate seen during the first day ( Figure lA) . As noted in the Materials and methods, the ELISA detects only native PGE2 and not the synthetic dmPGE2 used in this study to stimulate growth. Treatment of dmPGE2 also increased the steady-state endogenous PGE2 concentration by 17-fold from day 0 to day 1 during cell growth compared with the control (Figure iB) . At day 2, endogenous PGE2 concentration was threefold higher in the dmPGE2 treated cells than in the control cells. Thus, a correlation exists between the increase in cell number and increase in total endogenous PGE2 content during PC-3 cell growth, suggesting that the newly synthesized PGE2 plays an important role in maintaining cell proliferation.
Comparison of COX-2 message induction and changes in cell growth in response to various growth stimulators It has been previously reported that COX-2 expression was stimulated by tumour promoter phorbol ester in mouse fibroblasts (Kujubu et al, 1991; Herschman et al, 1993) as well as in human vascular endothelial cells (Hla and Neilson, 1992) . The effect of administration of PGE2 on COX-2 mRNA levels was compared with those of various growth stimulators including 10% serum and phorbol ester TPA (Figure 2A ). Both 10% FBS media and phorbol ester TPA (1.6 giM) were able to increase the steady-state levels of COX-2 mRNA accumulation by approximately fourfold compared with the untreated control. DmPGE2 (5 gig ml-1) upregulated COX-2 mRNA levels by 4.5-fold compared with the control culture. Expression of COX-1, however, was not detected in the PC-3 cells regardless of the stimulation (data not shown). We also compared the degree of growth stimulation of dmPGE2 with that of serum and TPA by measuring changes in the total DNA content following a 24-h growth stimulation ( Figure 2B ). Both 10% serum and TPA increased the cellular DNA content by British Journal of Cancer (1997) 75(8) 1.42-and 1.71-fold compared with the control, whereas dmPGE2 increased the DNA content by 1.64-fold compared with the control.
Time-dependent changes in the COX-2 mRNA levels following exogenous dmPGE2 administration
The time course of induction of COX-2 mRNA expression was investigated over a 3-h period of dmPGE2 treatment to PC-3 cells (Figure 3) . The steady-state COX-2 mRNA began to increase somewhere between 1 and 2 h following the addition of exogenous dmPGE2. At 3 h, the COX-2 mRNA reached its highest levels at 8.4-fold above the levels seen at the time of treatment. Beyond 3 h, the COX-2 mRNA levels decreased significantly and could still be detected at the 24-h time point with levels 3.6-fold higher than those of the control. However, at 10 rtg ml' dmPGE2, COX-2 mRNA accumulation was significantly decreased from the levels reached at 5 [ig ml dmPGE2 -back to the control levels.
Induction of COX-2 mRNA by dmPGE2 in other neoplastic cell lines We investigated whether the up-regulation of COX-2 mRNA by dmPGE2 in the PC-3 cells occurred in other prostate cancer cells, as well as in other cancer cells of different tissue origins. Another prostate cancer line, LNCaP, was chosen to illustrate the effect of dmPGE2 addition on COX-2 mRNA levels, as these cells are androgen dependent. Figure 5A shows that the LNCaP cells had high COX-2 mRNA levels, even in resting conditions, which might be due to an altered regulation of steady-state COX-2 message accumulation. However, as in PC-3 cells, exogenous dmPGE2 also increased the COX-2 mRNA levels time-dependently, with the highest accumulation seen 2 h after dmPGE2 addition. We also examined the COX-2 expression in human colonic carcinoma cells [derived from a familial adenomatous polyposis (Gardner's syndrome) patient], DiFi cells (Olive et al, 1993) and human breast carcinoma (MDA-MB-134) cells (Cailleau et al, 1974) . As shown in Figure SB , up-regulation COX-2 mRN accumulation in response to dmPGE2 administration was also observed in these two cell lines.
The effect of the NSAID flurbiprofen on the COX-2 mRNA accumulation
We further investigated whether the induction of COX-2 mRNA is also regulated by the endogenous dmPGE2. A flurbiprofen dose-response experiment was carried out to determine whether newly synthesized PGE2 contributes to the COX-2 mRNA accum- the DNA contents of growing PC-3 cells in response to exogenous dmPGE2 in the absence and presence of flurbiprofen. Flurbiprofen was able to reverse the increase in the cell number as well as DNA content of the growing cells treated with dmPGE2. As seen in Figure 6 , 1 FtM flurbiprofen markedly decreased the dmPGE2-induced COX-2 mRNA levels by fivefold compared with the levels attained when dmPGE2 alone was present. In cells treated with 5 [iM flurbiprofen, the COX-2 mRNA level was reduced even further. These data suggest that the newly synthesized, endogenous PGE2 is partly responsible for the signal regulating the upregulation of COX-2 mRNA levels.
The effect of translational inhibitor cycloheximide on COX-2 mRNA accumulation
In order to determine whether the induction of COX-2 mRNA accumulation by PGE2 was dependent on new protein synthesis, cycloheximide was used to block the cellular protein translation (Figure 7 ). In the absence of dmPGE2, cycloheximide increased the steady-state COX-2 mRNA accumulation to levels about sevenfold higher than those of the control. DmPGE2, however, only slightly potentiated the cycloheximide-induced increase in COX-2 mRNA levels to 1.2-fold above the levels seen with cycloheximide only.
DISCUSSION
The results of this study suggest that dmPGE2 increases PC-3 cell growth, total DNA content and endogenous PGE2 levels by inducing COX-2 mRNA transcript. The up-regulation of COX-2 mRNA in PC-3 cells seems to depend partly upon the new synthesis of PGE2. Moreover, flurbiprofen, a cyclo-oxygenase inhibitor, is able to decrease both growth and COX-2 mRNA levels. These findings are interesting as this cell line has previously been shown to be responsive to growth stimulation by the omega-6 polyunsaturated LA (an essential fatty acid), which is Connolly, 1991) . PGE2, as a downstream metabolite of LA, can increase cell growth as well as the enzyme responsible for its own synthesis. Indeed, the data presented in this paper provide the first evidence that dmPGE2 acts as a non-polypeptide growth factor in cancerous human cells. Previous studies from our laboratory have shown that dmPGE2 can act as an autocrine growth factor in bone formation and development both in vivo and in vitro (Hughes-Fulford et al, 1992) . Furthermore, PGE2 has recently been implicated in the growth and differentiation of human B-lymphocytes activated through their CD40 antigen (Garrone et al, 1994) . In spite of the evidence that PGE2 can act as a growth regulator, other data have demonstrated that high levels of PGE2 can cause growth arrest and, potentially, programmed cell death in a number of primary and established cell lines of immunological origins, such as thymocytes (Suzuki et al, 1991) and B-lymphocytes (Brown et al, 1992) . We, however, did not find any evidence that dmPGE2, at the concentrations used in this paper (as described in Materials and methods), promotes cell death in PC-3 cells.
One of the hallmarks of cellular stimulation in response to activation by hormones, growth factors or phorbol esters is the induction of the immediate-early gene expression. COX-2 has recently been classified as a member of this group (Kujubu et al, 1991; Herschman et al, 1993) . There are many lines of evidence showing that the gene encoding this enzyme is inducible by varieties of hormones and growth factors. For example, iloprost (a stable analogue of prostacyclin), PGE, or PGF2a increases the steadystate levels of COX-2 mRNA and protein in the mouse osteoblastic MC3T3-E1 cell line (Takahashi et al, 1994) . The data here add to our knowledge by showing for the first time that PGE2 can upregulate the mRNA levels of its own synthesizing enzyme, COX-2, in four human cancer cell lines. In this regard, it is conceivable that the cells continuously sustain their growth in part by using the extracellular PGE2 that they themselves produce and release to upregulate the expressions of COX-2 and possibly other growthrelated genes. Indeed, stimulation of c-fos and Egr-1 expression by arachidonic acid in 3T3 fibroblasts has been found to depend upon PGE2 formation (Danesch et al, 1994) . However, at present, we do not know the exact nature of the supporting role of PGE2 in the homeostasis of prostate cancer cells, such as that recently described for breast cancer cells (Schrey and Patel, 1995) . These investigators have found that breast fibroblasts, particularly under the influence of inflammatory mediators, such as interleukin l1 and bradykinin, provide a potentially rich source for PGE2 production in breast cancer cells, whereas significant contributions from the epithelial tumour component may be restricted to breast cancer cells exhibiting an invasive phenotype (Schrey and Patel, 1995) .
The up-regulation of COX-2 mRNA accumulation in PC-3 cells induced by dmPGE2 partly depends upon the new synthesis of PGE2 by the cells (Figure 6 ). However, this up-regulation does not seem to be due to a direct transcriptional effect of dmPGE2 on the COX-2 gene as the initial peak of the induction was seen at the 3-h time point following addition of exogenous dmPGE2 (Figure 3) . If a direct transcriptional effect had occurred, one would expect an increase in the mRNA levels within 15-30 min following addition of PGE2.
The administration of NSAID flurbiprofen decreased PC-3 cell growth (Table) and increased the COX-2 mRNA level brought about by exogenous dmPGE2 (Figure 6 ). However, it is still not clear to us whether this reduction in cell growth and COX-2 mRNA level was because of a direct inhibitory effect of flurbiprofen on COX-2 protein or other indirect effects associated with decreased expression of other growth genes. However, the results presented in this paper strongly suggest that this reduction in cell replication is due to a reduction in the new PGE2 synthesis by the NSAID, and hence the reduction in COX-2 gene expression and decrease in cell growth. It is therefore interesting to speculate whether NSAIDs can potentially be used as chemopreventive agents against the development of prostate cancer, as has been suggested for colon cancer (Thun et al, 1991; Earnest et al, 1992) .
As with other immediate-early genes, cycloheximide increased the steady-state COX-2 mRNA accumulation both in the absence and presence of dmPGE2 (Figure 7) . These data suggest the presence of a protein, possibly a ribonuclease, that normally reduces the steady-state level of cellular COX-2 mRNA, the synthesis of which is inhibited by the protein synthesis inhibitor cycloheximide. Similar effects of cycloheximide (or any other translation inhibitor) have been observed by many investigators (Kujubu et al, 1991; Stroebel and Goppelt-Struebe, 1994) , in which the most plausible explanation is that the agents inhibit the synthesis of a COX-2 mRNA degradation factor . In PC-3 cells, dmPGE2 only slightly potentiated the cycloheximideinduced COX-2 mRNA accumulation. These data suggest further that dmPGE2-induced increase in COX-2 mRNA levels required the synthesis of a new protein, perhaps a transcription factor, essential for the expression of the COX-2 gene.
In conclusion, we have shown evidence that suggests that dmPGE2 regulates the expression of COX-2 gene in two human prostatic carcinoma (e.g. PC-3 and LNCaP) cell lines. This regulation seems to be important in the maintenance of growth and homeostasis of the prostate cancer cells, as well as other cancerous human cells from different tissue origins (e.g. MDA-MB-134 and DiFi cells). Indeed, the data in this paper support our hypothesis that exogenous and newly synthesized PGE2 play a physiological role in the regulation of COX-2 expression and the growth of PC-3 cells, while NSAID (flurbiprofen) can down-regulate growth and COX-2 expression. As this cell line is responsive to growth stimulation by LA (Rose and Connolly, 1991) , the fact that its metabolite, PGE2, stimulates prostate cell growth brings us one step closer to defining a molecular link between dietary fat and increased cancer growth.
